STOCK TITAN
  1. Home
  2. News
  3. OCGN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated news page for Ocugen (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.

News
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
Rhea-AI Summary
Ocugen, Inc. (OCGN) receives RMAT designation from the FDA for OCU400, a gene therapy for retinitis pigmentosa (RP) associated with RHO mutations, based on promising Phase 1/2 clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
-
News
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Rhea-AI Summary
Ocugen, Inc. (NASDAQ: OCGN) has announced the dosing of the first patient in the ArMaDa Phase 1/2 clinical trial of OCU410, a potential one-time gene therapy for dry AMD. The trial aims to assess safety and efficacy for geographic atrophy secondary to dAMD, addressing the unmet need for durable and effective treatments for vision loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
clinical trial
-
News
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Rhea-AI Summary
Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at NobleCon19. The presentation will cover the company's gene and cell therapies, biologics, and vaccines, along with recent achievements. The webcast will be available on the company's website and Channelchek for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
conferences acquisition
News
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
Rhea-AI Summary
Ocugen, Inc. (NASDAQ: OCGN) announces the dosing of the first patient in the Phase 1/2 GARDian clinical trial for OCU410ST, a gene therapy candidate for Stargardt disease. This trial aims to address the unmet medical need for the 35,000 patients in the U.S. living with Stargardt disease. OCU410ST utilizes an AAV delivery platform for the retinal delivery of the RORA gene, representing Ocugen’s modifier gene therapy approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
clinical trial
-
News
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
Rhea-AI Summary
Ocugen Inc. (NASDAQ: OCGN) reported favorable safety and tolerability profile for OCU400 in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects, with promising Phase 1/2 study results showing stabilization or improvement of visual acuity in 83% of subjects. OCU500, Ocugen's inhaled mucosal vaccine candidate for COVID-19, was selected by the NIH/NIAID Project NextGen for clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
earnings
-
News
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
Rhea-AI Summary
Ocugen's Chief Scientific Officer will be a featured speaker at the 4th Annual Dry AMD Therapeutic Development Summit to discuss the complexity of Dry AMD and the development of OCU410, a gene therapy candidate for the treatment of geographic atrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
News
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
Rhea-AI Summary
Ocugen, Inc. will host a conference call and webcast to discuss its Q3 2023 financial results and provide a business update on November 9, 2023. Dial-in numbers and conference ID are provided for participation. A replay will be available on the investor site for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
conferences earnings
-
News
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
Rhea-AI Summary
NIAID to conduct clinical trials on Ocugen's mucosal vaccine candidate OCU500 via inhalation and nasal spray routes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
clinical trial
-
News
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
Rhea-AI Summary
Ocugen CEO to present at 2023 Cell & Gene Meeting on the Mesa, discussing positive Phase 1/2 OCU400 data results and plans for Phase 3 trial for cartilage repair product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
News
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
Rhea-AI Summary
Ocugen's Chief Scientific Officer, Arun Upadhyay, will be speaking at the 4th Annual Gene Therapy for Ophthalmic Disorders conference in Boston. He will discuss endpoints for gene therapy clinical trials and the design of first-in-human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
Stock OCGN logo
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

#3390 Ranked by Market Cap
#5296 Ranked by Stock Gains
N/A Ranked by Dividends

OCGN Stock Data

438.79M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
US
Malvern

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.